Based on findings, the European Society of Medical Oncology (ESMO) recommendations stated the addition of pertuzumab to trastuzumab and chemotherapy as the optimal neoadjuvant approach in HER2-positive high-risk early BC [9] and in 2015 the European Medicine Agency (EMA) approved this combination in the neoadjuvant setting of patients with HER2-positive, locally advanced, inflammatory, early BC at high risk of recurrence. This evidence concerns the gene ERBB2 and breast cancer.